PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

• Francesca Palandri,
• Stefanie Gröpper,
• Michael Loschi,
• Marcelo Bellesso,
• Sebastian Grosicki,
• Pilar Giraldo,
• Claire Harrison,
• Tracy Clevenger,
• Nikki Stuart,
• Hope Qamoos,
• Gregory Vosganian,
• Wayne P. Rothbaum,
• Srdan Verstovsek,
• Pankit Vachhani

Affiliations

Francesca Palandri

1 IRCCS S. Orsola-Malpighi, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Stefanie Gröpper

2 Marien Hospital Duesseldorf, Duesseldorf, Germany

Michael Loschi

3 Centre Hospitalier Universitaire (CHU) de Nice - Hopital L’Archet II, Nice, France

Marcelo Bellesso

4 IEP - Instituto de Ensino e Pesquisa Sao Lucas, São Paulo, Brazil

Sebastian Grosicki

5 Medical University of Silesia, Department of Hematology and Cancer Prevention, Katowice, Poland

Pilar Giraldo

6 Hospital Quironsalud de Zaragoza, Zaragoza, Spain

Claire Harrison

7 Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

Tracy Clevenger

8 Telios Pharma, Inc., Redwood City, United States

Nikki Stuart

8 Telios Pharma, Inc., Redwood City, United States

Hope Qamoos

8 Telios Pharma, Inc., Redwood City, United States

Gregory Vosganian

8 Telios Pharma, Inc., Redwood City, United States

Wayne P. Rothbaum

8 Telios Pharma, Inc., Redwood City, United States

Srdan Verstovsek

9 The University of Texas MD Anderson Cancer Center, Houston, United States

Pankit Vachhani

10 University of Alabama at Birmingham, Birmingham, United States